Formulation Development Outsourcing Market Research Report Information By Services (Pre Formulation Services and Formulation Optimization), By Dosage Form (Injectable, Oral, Topical, Inhaled, and Others), By Application (Oncology, Genetic Disorders, Neurology, Infectious Disease, Respiratory, Cardiovascular, and Others), By End User (Pharmaceutical and Biopharmaceutical, Government, and Academic Institutes) and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

1 EXECUTIVE SUMMARY

1.1 MARKET SYNOPSIS 16

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 17

2.2 RESEARCH OBJECTIVE 17

2.3 LIST OF ASSUMPTIONS & LIMITATIONS 17

3 RESEARCH METHODOLOGY

3.1 OVERVIEW 19

3.2 DATA MINING 19

3.3 SECONDARY RESEARCH 20

3.4 PRIMARY RESEARCH 21

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 21

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 22

3.5 FORECASTING TECHNIQUES 23

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 24

3.6.1 BOTTOM-UP APPROACH 24

3.6.2 TOP-DOWN APPROACH 25

3.7 DATA TRIANGULATION 25

3.8 VALIDATION 25

4 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES

4.1 INTRODUCTION 26

4.2 PREFORMULATION SERVICES 27

4.2.1 FORMULATION DISCOVERY 28

4.2.2 PRECLINICAL SERVICES 28

4.2.3 ANALYTICAL SERVICES 29

4.3 FORMULATION OPTIMIZATION 29

4.3.1 PHASE I 30

4.3.2 PHASE II 30

4.3.3 PHASE III 31

4.3.4 PHASE IV 31

5 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM

5.1 INTRODUCTION 32

5.2 INJECTABLE 34

5.3 ORAL 34

5.4 TOPICAL 35

5.5 INHALED 35

5.6 OTHERS 36

6 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION

6.1 INTRODUCTION 37

6.2 ONCOLOGY 39

6.3 GENETIC DISORDERS 40

6.4 NEUROLOGY 40

6.5 INFECTIOUS DISEASES 41

6.6 RESPIRATORY 41

6.7 CARDIOVASCULAR 42

6.8 OTHERS 42

7 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER

7.1 INTRODUCTION 43

7.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 44

7.3 GOVERNMENT & ACADEMIC INSTITUTES 44

8 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY REGION

8.1 INTRODUCTION 45

8.2 AMERICAS 46

8.2.1 NORTH AMERICA 48

8.2.1.1 US 51

8.2.1.2 CANADA 53

8.2.2 LATIN AMERICA 55

8.3 EUROPE 58

8.3.1 WESTERN EUROPE 61

8.3.1.1 GERMANY 63

8.3.1.2 FRANCE 65

8.3.1.3 UK 67

8.3.1.4 ITALY 69

8.3.1.5 SPAIN 71

8.3.1.6 REST OF WESTERN EUROPE 73

8.3.2 EASTERN EUROPE 75

8.4 ASIA-PACIFIC 78

8.4.1 JAPAN 80

8.4.2 CHINA 82

8.4.3 INDIA 84

8.4.4 AUSTRALIA 86

8.4.5 SOUTH KOREA 88

8.4.6 REST OF ASIA-PACIFIC 90

8.5 MIDDLE EAST & AFRICA 93

8.5.1 MIDDLE EAST 95

8.5.2 AFRICA 97

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW 100

9.2 MARKET SHARE ANALYSIS 100

9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES MARKET 101

9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES MARKET 102

9.5 KEY DEVELOPMENT ANALYSIS 102

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 103

9.6.1 ACQUISITION ACTIVITIES 103

9.6.2 EXPANSION 104

9.6.3 FINANCIAL MATRIX 104

9.6.4 R&D EXPENDITURE 104

10 COMPANY ANALYSIS

10.1 CHARLES RIVER LABORATORIES 105

10.2 AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED 106

10.3 CATALENT, INC. 108

10.4 LABORATORY CORPORATION OF AMERICA 109

10.5 SYNGENE INTERNATIONAL LTD. 110

10.6 IRISYS, LLC 111

10.7 INTERTEK 112

10.8 PIRAMAL ENTERPRISES LTD. 113

10.9 QUOTIENT SCIENCES 114

10.10 PATHEON (THERMO FISHER SCIENTIFIC) 115

10.11 EMERGENT BIOSOLUTIONS INC. 116

10.12 LONZA 117

10.13 PCI 118

10.14 DR. REDDY’S LABORATORIES LTD. 118

11 COMPANY PROFILES

11.1 AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED 119

11.1.1 COMPANY OVERVIEW 119

11.1.2 FINANCIAL OVERVIEW 119

11.1.3 PRODUCTS/SERVICES OFFERED 119

11.1.4 KEY DEVELOPMENTS 121

11.1.5 SWOT ANALYSIS 122

11.1.6 KEY STRATEGIES 122

11.2 IRISYS, INC. 123

11.2.1 COMPANY OVERVIEW 123

11.2.2 FINANCIAL OVERVIEW 123

11.2.3 PRODUCTS/SERVICES OFFERED 123

11.2.4 KEY DEVELOPMENTS 124

11.2.5 SWOT ANALYSIS 125

11.2.6 KEY STRATEGIES 125

11.3 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 126

11.3.1 COMPANY OVERVIEW 126

11.3.2 FINANCIAL OVERVIEW 126

11.3.3 PRODUCTS OFFERED 127

11.3.4 KEY DEVELOPMENTS 128

11.3.5 SWOT ANALYSIS 128

11.3.6 KEY STRATEGIES 128

11.4 INTERTEK GROUP PLC 129

11.4.1 COMPANY OVERVIEW 129

11.4.2 FINANCIAL OVERVIEW 129

11.4.3 PRODUCTS/SERVICES OFFERED 130

11.4.4 KEY DEVELOPMENTS 131

11.4.5 SWOT ANALYSIS 131

11.4.6 KEY STRATEGIES 131

11.5 CATALENT, INC. 132

11.5.1 COMPANY OVERVIEW 132

11.5.2 FINANCIAL OVERVIEW 132

11.5.1 PRODUCTS/SERVICES OFFERED 133

11.5.2 KEY DEVELOPMENTS 134

11.5.3 SWOT ANALYSIS 134

11.5.4 KEY STRATEGIES 135

11.6 SYGENE INTERNATIONAL LIMITED 136

11.6.1 COMPANY OVERVIEW 136

11.6.2 FINANCIAL OVERVIEW 136

11.6.3 PRODUCTS/SERVICES OFFERED 137

11.6.4 KEY DEVELOPMENTS 138

11.6.5 SWOT ANALYSIS 139

11.6.6 KEY STRATEGIES 139

11.7 LABORATORY CORPORATION OF AMERICA HOLDINGS 140

11.7.1 COMPANY OVERVIEW 140

11.7.2 FINANCIAL OVERVIEW 140

11.7.3 PRODUCTS/SERVICES OFFERED 141

11.7.4 KEY DEVELOPMENTS 141

11.7.5 SWOT ANALYSIS 142

11.7.6 KEY STRATEGIES 142

11.8 PATHEON (THERMO FISHER SCIENTIFIC) 143

11.8.1 COMPANY OVERVIEW 143

11.8.2 FINANCIAL OVERVIEW 143

11.8.3 PRODUCTS/SERVICES OFFERED 144

11.8.4 KEY DEVELOPMENTS 145

11.8.5 SWOT ANALYSIS 145

11.8.6 KEY STRATEGIES 146

11.9 QUOTIENT SCIENCES 147

11.9.1 COMPANY OVERVIEW 147

11.9.2 FINANCIAL OVERVIEW 147

11.9.3 PRODUCTS/SERVICES OFFERED 147

11.9.4 KEY DEVELOPMENTS 148

11.9.5 SWOT ANALYSIS 148

11.9.6 KEY STRATEGIES 148

11.10 EMERGENT BISOLUTIONS INC. 149

11.10.1 COMPANY OVERVIEW 149

11.10.2 FINANCIAL OVERVIEW 149

11.10.3 PRODUCTS/SERVICES OFFERED 149

11.10.4 KEY DEVELOPMENTS 150

11.10.5 SWOT ANALYSIS 150

11.10.6 KEY STRATEGIES 150

12 APPENDIX

12.1 REFERENCES 151

12.2 RELATED REPORTS 152

13 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 17

TABLE 2 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022-2030 (USD MILLION) 27

TABLE 3 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE, 2022-2030

(USD MILLION) 27

TABLE 4 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY REGION, 2022-2030

(USD MILLION) 27

TABLE 5 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION DISCOVERY, BY REGION, 2022-2030

(USD MILLION) 28

TABLE 6 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PRECLINICAL SERVICES, BY REGION, 2022-2030

(USD MILLION) 28

TABLE 7 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR ANALYTICAL SERVICES, BY REGION, 2022-2030

(USD MILLION) 29

TABLE 8 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE, 2022-2030

(USD MILLION) 29

TABLE 9 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY REGION, 2022-2030

(USD MILLION) 29

TABLE 10 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PHASE I, BY REGION, 2022-2030 (USD MILLION) 30

TABLE 11 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PHASE II, BY REGION, 2022-2030 (USD MILLION) 30

TABLE 12 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PHASE III, BY REGION, 2022-2030 (USD MILLION) 31

TABLE 13 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PHASE IV, BY REGION, 2022-2030 (USD MILLION) 31

TABLE 14 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022-2030 (USD MILLION) 33

TABLE 15 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR INJECTABLE, BY REGION, 2022-2030 (USD MILLION) 34

TABLE 16 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR ORAL, BY REGION, 2022-2030 (USD MILLION) 34

TABLE 17 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR TOPICAL, BY REGION, 2022-2030 (USD MILLION) 35

TABLE 18 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR INHALED, BY REGION, 2022-2030 (USD MILLION) 35

TABLE 19 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION) 36

TABLE 20 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 39

TABLE 21 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR ONCOLOGY, BY REGION, 2022-2030 (USD MILLION) 39

TABLE 22 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR GENETIC DISORDERS, BY REGION, 2022-2030

(USD MILLION) 40

TABLE 23 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR NEUROLOGY, BY REGION, 2022-2030 (USD MILLION) 40

TABLE 24 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2022-2030

(USD MILLION) 41

TABLE 25 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR RESPIRATORY, BY REGION, 2022-2030 (USD MILLION) 41

TABLE 26 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR CARDIOVASCULAR, BY REGION, 2022-2030 (USD MILLION) 42

TABLE 27 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION) 42

TABLE 28 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022-2030 (USD MILLION) 44

TABLE 29 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL

COMPANIES, BY REGION, 2022-2030 (USD MILLION) 44

TABLE 30 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR GOVERNMENT & ACADEMIC INSTITUTES, BY REGION

, 2022-2030 (USD MILLION) 44

TABLE 31 GLOBAL: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY REGION, 2022–2030 (USD MILLION) 46

TABLE 32 AMERICAS: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY REGION, 2022–2030 (USD MILLION) 46

TABLE 33 AMERICAS: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 46

TABLE 34 AMERICAS: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 47

TABLE 35 AMERICAS: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 47

TABLE 36 AMERICAS: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 47

TABLE 37 AMERICAS: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 48

TABLE 38 AMERICAS: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 48

TABLE 39 NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 48

TABLE 40 NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 49

TABLE 41 NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE

2022–2030 (USD MILLION) 49

TABLE 42 NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE

2022–2030 (USD MILLION) 49

TABLE 43 NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 50

TABLE 44 NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 50

TABLE 45 NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 51

TABLE 46 US: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 51

TABLE 47 US: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 51

TABLE 48 US: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 52

TABLE 49 US: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 52

TABLE 50 US: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 53

TABLE 51 US: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 53

TABLE 52 CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 53

TABLE 53 CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 54

TABLE 54 CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 54

TABLE 55 CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 54

TABLE 56 CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 55

TABLE 57 CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 55

TABLE 58 LATIN AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 55

TABLE 59 LATIN AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE

2022–2030 (USD MILLION) 56

TABLE 60 LATIN AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE

2022–2030 (USD MILLION) 56

TABLE 61 LATIN AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 56

TABLE 62 LATIN AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 57

TABLE 63 LATIN AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 57

TABLE 64 EUROPE FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY REGION, 2022-2030 (USD MILLION) 58

TABLE 65 EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 58

TABLE 66 EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 58

TABLE 67 EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 59

TABLE 68 EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 59

TABLE 69 EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 60

TABLE 70 EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 60

TABLE 71 WESTERN EUROPE FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY , 2022-2030 (USD MILLION) 61

TABLE 72 WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 61

TABLE 73 WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE

2022–2030 (USD MILLION) 61

TABLE 74 WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE

2022–2030 (USD MILLION) 62

TABLE 75 WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 62

TABLE 76 WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 63

TABLE 77 WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 63

TABLE 78 GERMANY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 63

TABLE 79 GERMANY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 64

TABLE 80 GERMANY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 64

TABLE 81 GERMANY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 64

TABLE 82 GERMANY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 65

TABLE 83 GERMANY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 65

TABLE 84 FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 65

TABLE 85 FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 66

TABLE 86 FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 66

TABLE 87 FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 66

TABLE 88 FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 67

TABLE 89 FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 67

TABLE 90 UK: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 67

TABLE 91 UK: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 68

TABLE 92 UK: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 68

TABLE 93 UK: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 68

TABLE 94 UK: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 69

TABLE 95 UK: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 69

TABLE 96 ITALY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 69

TABLE 97 ITALY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 70

TABLE 98 ITALY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 70

TABLE 99 ITALY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 70

TABLE 100 ITALY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 71

TABLE 101 ITALY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 71

TABLE 102 SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 71

TABLE 103 SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 72

TABLE 104 SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 72

TABLE 105 SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 72

TABLE 106 SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 73

TABLE 107 SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 73

TABLE 108 REST OF WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 73

TABLE 109 REST OF WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES,

BY TYPE 2022–2030 (USD MILLION) 74

TABLE 110 REST OF WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION,

BY PHASE 2022–2030 (USD MILLION) 74

TABLE 111 REST OF WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030

(USD MILLION) 74

TABLE 112 REST OF WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030

(USD MILLION) 75

TABLE 113 REST OF WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 75

TABLE 114 EASTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 75

TABLE 115 EASTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE

2022–2030 (USD MILLION) 76

TABLE 116 EASTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE

2022–2030 (USD MILLION) 76

TABLE 117 EASTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 76

TABLE 118 EASTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 77

TABLE 119 EASTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 77

TABLE 120 ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 78

TABLE 121 ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 78

TABLE 122 ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 78

TABLE 123 ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE

2022–2030 (USD MILLION) 79

TABLE 124 ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 79

TABLE 125 ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 80

TABLE 126 ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 80

TABLE 127 JAPAN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 80

TABLE 128 JAPAN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 81

TABLE 129 JAPAN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 81

TABLE 130 JAPAN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 81

TABLE 131 JAPAN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 82

TABLE 132 JAPAN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 82

TABLE 133 CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 82

TABLE 134 CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 83

TABLE 135 CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 83

TABLE 136 CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 83

TABLE 137 CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 84

TABLE 138 CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 84

TABLE 139 INDIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 84

TABLE 140 INDIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 85

TABLE 141 INDIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 85

TABLE 142 INDIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 85

TABLE 143 INDIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 86

TABLE 144 INDIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 86

TABLE 145 AUSTRALIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 86

TABLE 146 AUSTRALIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 87

TABLE 147 AUSTRALIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 87

TABLE 148 AUSTRALIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 87

TABLE 149 AUSTRALIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 88

TABLE 150 AUSTRALIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 88

TABLE 151 SOUTH KOREA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 88

TABLE 152 SOUTH KOREA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE

2022–2030 (USD MILLION) 89

TABLE 153 SOUTH KOREA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE

2022–2030 (USD MILLION) 89

TABLE 154 SOUTH KOREA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 89

TABLE 155 SOUTH KOREA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 90

TABLE 156 SOUTH KOREA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 90

TABLE 157 REST OF ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 90

TABLE 158 REST OF ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE

2022–2030 (USD MILLION) 91

TABLE 159 REST OF ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE

2022–2030 (USD MILLION) 91

TABLE 160 REST OF ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 91

TABLE 161 REST OF ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 92

TABLE 162 REST OF ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 92

TABLE 163 MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 93

TABLE 164 MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 93

TABLE 165 MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE

2022–2030 (USD MILLION) 93

TABLE 166 MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION,

BY PHASE 2022–2030 (USD MILLION) 94

TABLE 167 MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 94

TABLE 168 MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 95

TABLE 169 MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 95

TABLE 170 MIDDLE EAST: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 95

TABLE 171 MIDDLE EAST: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 96

TABLE 172 MIDDLE EAST: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE

2022–2030 (USD MILLION) 96

TABLE 173 MIDDLE EAST: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 96

TABLE 174 MIDDLE EAST: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 97

TABLE 175 MIDDLE EAST: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 97

TABLE 176 AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 97

TABLE 177 AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030

(USD MILLION) 98

TABLE 178 AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030

(USD MILLION) 98

TABLE 179 AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 98

TABLE 180 AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 99

TABLE 181 AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 99

TABLE 182 MOST ACTIVE PLAYER IN THE GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES 102

TABLE 183 ACQUISITION ACTIVITIES 103

TABLE 184 EXPANSION 104

TABLE 185 AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED: PRODUCTS/SERVICES OFFERED 119

TABLE 186 IRYSIS, INC.: PRODUCTS/SERVICES OFFERED 123

TABLE 187 CHARLES RIVER LABORATORIES INTERNATIONAL INC: PRODUCTS/SERVICES OFFERED 127

TABLE 188 CHARLES RIVER LABORATORIES: KEY DEVELOPMENTS 128

TABLE 189 INTERTEK GROUP PLC: PRODUCTS/SERVICES OFFERED 130

TABLE 190 INTERTEK GROUP PLC: KEY DEVELOPMENTS 131

TABLE 191 CATALENT INC: PRODUCTS/SERVICES OFFERED 133

TABLE 192 SYGENE INTERNATIONAL LIMITED: PRODUCTS/SERVICES OFFERED 137

TABLE 193 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES OFFERED 141

TABLE 194 THERMO FISHER SCIENTIFIC: PRODUCTS/SERVICES OFFERED 144

TABLE 1 QUOTIENT SCIENCES: PRODUCTS/SERVICES OFFERED 147

TABLE 2 EMERGENT BIOSOLUTIONS INC: PRODUCTS/SERVICES OFFERED 149

14 LIST OF FIGURES

FIGURE 1 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET STRUCTURE 18

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 24

FIGURE 3 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022 & 2030 (USD MILLION) 26

FIGURE 4 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022 & 2030 (USD MILLION) 33

FIGURE 5 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022 & 2030 (USD MILLION) 38

FIGURE 6 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022 & 2030 (USD MILLION) 43

FIGURE 7 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET SHARE, BY REGION, 2022 & 2030 (USD MILLION) 45

FIGURE 8 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES MARKET, MARKET SHARE ANALYSIS, 2022 (%) 100

FIGURE 9 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES

MARKET 101

FIGURE 10 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES MARKET, COMPETITIVE LANDSCAPE 102

FIGURE 11 SALES & OPERATING INCOME MARGIN 104

FIGURE 12 R&D EXPENDITURE 104

FIGURE 13 AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED: SWOT ANALYSIS 122

FIGURE 14 IRISYS, INC: SWOT ANALYSIS 125

FIGURE 15 CHARLES RIVER LABORATORIES INTERNATIONAL INC.: FINANCIAL OVERVIEW SNAPSHOT 126

FIGURE 16 CHARLES RIVER LABORATORIES INTERNATIONAL INC: SWOT ANALYSIS 128

FIGURE 17 INTERTEK GROUP PLC: FINANCIAL OVERVIEW SNAPSHOT 129

FIGURE 18 INTERTEK GROUP PLC: SWOT ANALYSIS 131

FIGURE 19 CATALENT INC: FINANCIAL OVERVIEW SNAPSHOT 132

FIGURE 20 CATALENT INC.: SWOT ANALYSIS 134

FIGURE 21 SYGENE INTERNATIONAL LIMITED: FINANCIAL OVERVIEW SNAPSHOT 136

FIGURE 22 SYGENE INTERNATIONAL LIMITED: SWOT ANALYSIS 139

FIGURE 23 LABORATORY CORPORATION OF AMERICA HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT 140

FIGURE 24 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS 142

FIGURE 25 THERMOFISHER SCIENTIFIC: SWOT ANALYSIS 145

FIGURE 26 QUOTIENT SCIENCES: SWOT ANALYSIS 148

FIGURE 27 EMERGENT BIOSOLUTIONS INC.: SWOT ANALYSIS 150